In contrast, neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer characterized by decreased AR signaling, increased expression of neuroendocrine markers, and an insensitivity to AR-directed therapies (1–3). This evidence concerns the gene AR and prostate carcinoma.